header image

Page 74«..1020..73747576..8090..»

Winn Feline Awards 11 Study Grants – VetPracticeNews.com

The foundation has awarded $214,000 for 11 feline health studies.

By Veterinary Practice News Editors

Published: 2017.06.14 04:34 PM

Pixabay

The Winn Feline Foundation, a Wyckoff, N.J., nonprofit that supports studies to improve cat health and has funded almost $6 million in health research for cats at more than30 partner institutionsworldwide,announced in April that it awarded more than $214,000 for 11 feline health studies.

The research studies funded include:

Winn Feline Foundation is able to fund additional feline health studies each year through a grant from the George Sydney and Phyllis Redman Miller Trust. Via special funding through the Bria Fund for FIP research, the foundation also is calling for research proposals that address FIP genetics and molecular biology, prevention, novel diagnostics, and safe and effective treatments.

Aug. 7 is the deadline for receipt of applications for Miller Trust and FIP grants. The maximum grant is $35,000. Details are availablehere.

The Occupational Employment and Wages report from the U.S. Department of Labor Bureau shows veterinarians are earning a higher salary, but not enough to pay off student debts.

Veterinarian-turned-painter Ande Hall, embarking on a second career as an artist, is getting noticed for her talents.

The U.S. Food and Drug Administration's Center for Veterinary Medicine completed the second phase of their Animal Drugs @ FDA on June 8.

Read this article:
Winn Feline Awards 11 Study Grants - VetPracticeNews.com

Stem cells might not be a good option for your kid’s sports injury – Miami Herald

Stem cells might not be a good option for your kid's sports injury
Miami Herald
... mesenchymal stem cells to help athletes return to their sport after injury. Yet many patients and caregivers struggle to make an informed decision about the use of PRP and stem cells in injury recovery as these are newer, and thus less understood ...

See original here:
Stem cells might not be a good option for your kid's sports injury - Miami Herald

Annual Summit on Cell Therapy and Molecular Medicine …

Sessions/Tracks

Track 1: Cell Therapy

Cell therapy or cytotherapy is the transfer of cells into a patient with a goal of improving the disease. From beginning blood transfusions were considered to be the first type of cell therapy to be practised as routine. Later, Bone marrow transplantation has also become a well established concept which involves treatment of many kind of blood disorders including anemia, leukemia, lymphyoma and rare immunodeficiency diseases. Alternative medical practitioners perform cell therapy in the form of several different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. It has been claimed by the proponents of cell therapy that it has been used successfully to repair spinal cord injuries, strengthen weaken immune system, treats autoimmune diseases like AIDS, help patients with neurological disorders like Alzheimers disease, parkinsons disease and epilepsy.

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19th International Conference on Cell and Gene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7th Spring Meeting Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.

Track 2: Gene Therapy

Gene therapy basically involves the introduction or alteration of genetic material within a cell or organism with an intention of curing the disease. Both cell therapy and gene therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in DNA or cellular population respectively. The discovery of recombinant DNA technology in the 1970s provided tools to efficiently develop gene therapy. Scientists use these techniques to readily manipulate viral genomes, isolate genes and identify mutations involved in human disease, characterize and regulate gene expressions, and engineer various viral and non viral vectors. Various long term treatments for anemia, haemophilia, cystic fibrosis, muscular dystrophy, Gauschers disease, lysosomal storage diseases, cardiovascular diseases, diabetes and diseases of bones and joints are resolved through successful gene therapy and are elusive today.

Related Conferences

Annual Summit onCell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 3:Molecular Medicine

Molecular Medicineis a branch of medicine that develops ways to diagnose and treat diseases by understanding the ways genes, proteins and other cellular molecules work. It is a broad field where physical, chemical, biological,bioinformatics, and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of the disease, and to develop molecular interventions to correct them. Molecular Medicine has now a days proved to be an exciting field of research as some of the recent advancements has led to improved clinical benefits for human health. These are LPS- induced inflammatory response is suppressed by Wnt inhibitors, Dickkopf-1 and LGK974, Selective inhibition ofEbolaentry with selective estrogen receptor modulators by disrupting the endolysosomal calcium, ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signalling and many more.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 4:Immunotherapy

Due to rapidly advancing field of cancer immunology in past few years, there has been production of several new methods of treating cancer called Immunotherapies. Immunotherapy is a type of treatment that increases the strength of immune response against tumors either by stimulating the activities of specific components of immune system or by counteracting signals produced by cancer cells that suppress immune responses. Some types of immunotherapy are also called as biologic therapy or biotherapy. Recent advancements in cancer immunotherapies have provided new therapeutic approaches. These include tumor-associated macrophages as treatment targets in oncology, in-situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, immune checkpoint blockade and associated endocrinopathies and many more.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Genetic Medicine orMedical Geneticsis the branch of medicine that differs from human genetics, and involves the diagnosis and management of hereditary disorders. Human genetics may or may not apply to medicine, but medical genetics refers to the application of genetics to medical care. Genetic Medicine basically involves different areas such asgene therapy, personalized medicine, predictive medicine and the rapidly emerging new medical specialty. Now a days, medical genetics has wide range of scopes in many conditions involving birth defects and dysmorphology,autism, mental retardation, skeletal dysplasia, mitochondrial disorders, cancer genetics, connective tissue disorders and some more.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 6: Clinical Trials in Cell and Gene Therapy

A clinical trial is a research study that tests how well new medical approaches work on people and determines if a treatment is safe and effective. The new cell and gene therapies (CGTs) that are advancing from the laboratory into early phase clinical trials has proven to be a complex task even for experienced investigators . As a result of wide variety of CGT products and their potential applications, a case by case assessment is warranted for the design of each clinical trial. Some of the latest and advanced clinical trials include safety and efficacy trial of AAV gene therapy in patients with CNGA3 Achromatopsia, A clinical trial for treatment of Aromatic L- Amino acid Decarboxylase (AADC) deficiency using AAV2-hAADC- An expansion and Glypican 3-specific Chimeric antigenic receptor expressed in T cells for patients with pediatric solid tumors.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 7: Cell Therapy Bioprocessing

Cell Therapy Bioprocessing activity mainly focuses to accelerate the safe, cost- effective translations and clinical efficacious of cell therapies into commercial products. This activity covers the entire range of cell therapy activities as well as tissue engineering. In order to succeed, commercial success of at least a few late-stage products are required to develop which will be funded to develop next generation tools and technologies for this field. Recent achievements include, preclinical filing for Phase 1 clinical trials for cell therapy in acute spinal cord injury, clinical proof of concept studies in tissue- engineered trachea, clinical trials for tissue-engineered larynx and routine clinical practice in the regeneration of corneas. The future research priorities will focus on novel cell and bioprocess engineering techniques in order to improve the manufacturing efficacy and methods for health technology assessment to support rapid clinical adoption of new cell therapies.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cell and Gene Therapy products manufacturing focuses on various strategies like the manufacturing process must protect the product, patient, should focus on product characterization, process control, high throughput and parallel processing to achieve scale. The process/analytical development throughout clinical trials involve ongoing, iterative development of manufacturing process and characterization of profile and FDA expecting increasing control and characterization as clinical development progresses. Steps involved in individualized manufacturing and running in parallel for high throughput involves cell selection, expansion, activation, centrifugation and cryopreservation.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 9: Rare Diseases & Orphan drugs

Rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10,000 persons in the European Community according to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare if taken individually but they affect a significant proportion of the European population when considered as a single group. Several initiatives have been taken at international, European and national level to tackle public health as well as research issues related to diagnosis, prevention, treatment and surveillance of these diseases. An Orphan drug can be defined as the one that is used to treat an orphan disease. An orphan disease in USA is defined as the one that affects fewer than 200000 individuals, but in Japan the number is 50,000 and in Australia is 2000. In past 20 years efforts have been made to encourage companies to develop orphan drugs. The Orphan Drug Act in the USA (1983) was succeeded by similar legislation in Japan (1985), Australia (1997), and the European Community (2000). The encouragement takes three forms: tax credits and research aids, simplification of marketing authorization procedures, and extended market exclusively.

Related Conferences

Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Stem cells can self renew themselves and differentiate or develop into more specialised cells. They are the foundation for every organ and tissue in our body. Due to this ability of the stem cells, they have tremendous promise to help us understand and treat a wide range of diseases, injuries and other health related problems. Bone marrow transplantation is the most widely used stem cell therapy , but some of the therapies are derived from umbilical cord blood are also in use today. Likewise, blood stem cells are used to treat diseases of blood, a therapy that has saved thousands of lives of children with leukemia. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues and the healing process relies on stem cells with implanted tissue.Regenerative medicines aims to replace tissues or organs that have been damaged by disease, trauma, or congenital issues which is in contrast to the current clinical strategy that focuses primarily on treating the symptoms. These regenerative medicines have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, and neuro degenerative diseases. Cell treatment is the quickest developing fragment of regenerative drug and this undeveloped cell treatment is making up the biggest part of this business sector.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cancer is a process where the cells grow aberrantly and this growth of cancer cells results in damage of normal tissues, causing loss of function and often pain. The cancer therapeutic drugs are those drugs that block the growth and spread of cancer by interfering with specific molecules (molecular targets) that are involved in the growth, progression and spread of cancer. Moreover, gene therapy approaches may be designed to directly kill tumor cells using tumor killing viruses, or through the introduction of genes termed as suicide genes into the tumor cells. The Food and Drug Administration (FDA) has approved many cancer therapies in order to treat specific types of cancers. To develop targeted therapies it requires the identification of good targets that is, those targets that play a key role in cancer cell growth and survival. One way to identify potential targets is to compare the amounts of individual proteins in cancer cells with those present in normal cells. Gene silencing has also been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth, blood vessel formation and allow resistance for chemotherapy.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 12:Nuclear Medicine

Nuclear medicineis a branch of medical imaging that involves the application of radioactive substances called radiotracers that are generally injected into the bloodstream, inhaled or swallowed. Theradiotracerthen travels through the area being examined and gives off energy in the form of gamma rays, which are detected by a special camera and a computer to create images of inside the body. It is used to diagnose or determine the severity of or treat different types of diseases like many types of cancers, heart disease, neurological disease, gastrointestinal disease, and other abnormalities inside the body. As nuclear medicine techniques are able to identify molecular activity within the body, they offer the capability to detect diseases in its very early stages as well as a patients immediate response to therapeutic interventions. There are two most common imaging methods in nuclear medicine, one isSingle Photon Emission Computed Tomographyor SPECT and the other is Positron Emission Tomography or PET scans.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 13: Advances in Cell Engineering, Imaging and Screening

In recent times, advancements in cell engineering, imaging and screening has reached a great height in the field of science & technology and also in the business world. It has attracted many scientists from academia and also established or emerging companies in the field to present their latest scientific achievements and exciting technological solutions through presentations in several sessions. This has helped in improving the scientific knowledge among the people, scientists, researchers and exhibitors from all over the world thus enhancing their scientific curiosity and providing robust solutions against technological issues.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Track 14: Synthetic Biology and Genetic modifications of cells

Synthetic Biology is one of the emerging field of research that can be broadly described as the design and construction of novel artificial biological pathways, organisms or devices or the redesigning of existing natural biological systems. Genome editing with engineered nucleases is a type of genetic engineering in which DNA is either inserted, replaced or deleted in the genome of an organism using engineered nucleases or molecular scissors. These nucleases hence create site specific double stranded breaks (DSBs) at desired locations in the genome. The induced double stranded breaks are repaired through non homologous end- joining (NHEJ) or homologous recombination (HR), thus resulting in targeted mutations (edits). Scientists now a days use various engineered nucleases in order to bring desired changes in the human genome.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Biobanking 2016

Sensing the raising importance of Biobanks,Conference LLChosted the 2nd International Conference & Exhibition on Tissue Preservation and Biobanking(Biobanking-2016), duringSeptember 12-13, 2016inPhiladelphia, USAwith a theme Global Innovations in Tissue preservation and Biobanking Technologies. Benevolent response and active participations were received from the Editorial Board Members of Conference LLC Journals as well as from the Biobank project managers, Embryologists, Hematologists, Stem Cell researchers, Scientists, Doctors, Students and Leaders from the fields of Cell and Stem Cell Research, who made this event inspiringly successful.

TheBiobanking-2016 Conferencewas carried out through various sessions with discussions on the following thought provoking and cerebrating scientific tracks:

Human cancer biobank

Biorepository & Biospecimen

Disease based biobank

Cryopreservation Methods

Vitrification

Brain Banking

Biobank Ethics

Biobank in Microbiology

Next Generation Biobanking

Biobank in Genomics

Fertility biobanks

Germplasm Bank

Immune banking

Biobank Applications

Biobanking Informatics

Market Analysis in Biobanking

Tissue engineering

. Stem cell Biobanking

The Organizing Committee would like to thank the moderatorDr.Mary A Hall,UT health sciences, USAandDr. Elena Salvaterra,Air liquide Sanit Service, Italyfor their contribution which resulted in smooth functioning of the conference.

The conference was initiated and embarked with an opening ceremony followed by Keynote presentations, workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The peerless people who promulgated the theme with their Keynote presentations were;

Kelvin GM Brockbank-Ice-free banking by vitrification of tissues(Tissue Testing Technologies LLC, USA)

Simone Chevalier- The Quebec procure prostate cancer biobank: A unique resource for comprehensive studies of the disease(McGill Urology Director of Research, Canada)

Stephen C Peiper-Biospecimen repository genomic annotations in the precision medicine era(Thomas Jefferson University, USA)

Fiorella Guadagni-Biobanks as a pivotal research infrastructure in precision medicine (San Raffaele Rome University, Italy)

Yoed Rabin-Mechanical stress and structural integrity in vitrification(Carnegie Mellon University, USA)

Mitchel C. Schiewe-Applying the KISS principle with vitrification: Safety and quality control concerns in assisted reproductive technologies(Ovagen Fertility, USA)

Various sessions were chaired and co-chaired by: Kelvin GM Brockbank (Tissue Testing Technologies LLC, USA);Simone Chevalier (McGill Urology Director of Research, Canada), USA; Charles W Wang, (Shanghai Jiao Tong University, China);Yaffa Rubinstein (National Institute of Health, USA).

Conference Series LLC has taken the privilege of felicitating Biobanking-2016 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this conference.

The esteemed guests, keynote speakers and researchers shared their innovative research and vast experience through their informative presentations at the podium ofBiobanking-2016.We are glad to inform that all accepted abstracts for the conference have been published inJournal of Tissue Science & Engineering: Open Accessas a special issue.

We are also obliged to various experts, company representatives and other eminent scientists who supported the conference by facilitating the discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference,Conference Series LLC would like to proudly announce the commencement of the 3rd International Conference & Exhibition on Tissue Preservation and Biobanking" to be organized duringAugust 23-24, 2017atSan Francisco, USA.

Mark your calendars for the upcoming Conference; we are hoping to see you soon!

For more details:http://biobanking.conferenceseries.com/

Read more here:
Annual Summit on Cell Therapy and Molecular Medicine ...

Abused pup receives cutting-edge stem cell therapy – fox5sandiego.com

Please enable Javascript to watch this video

SAN DIEGO Abused orphan pup "Dwyane," who has severe disfigurements, is on the road to recovery after stem cell therapy by a Poway-based company.

The one-year-old puppy was reportedly kicked, beaten and forced to wear a wire muzzle before he was rescued in Tijuana.

Last month, he was taken to Helen Woodward Animal Center in Rancho Sante Fe. Since then, the dog has undergone several procedures, including a hip surgery Tuesday.

Animal hospital officials said Dwaynes work isnt over yet, as he still needs major reconstruction to his elbow and additional facial surgeries to help him breathe easier.

There is no risk involved because we use the dog's own tissue to isolate the stem cell, said Dr. Jeffrey Schaffer with VetStem of Poway.

Today, we gave the injection of the stem cells in the hip and then a slow one through the vein," said Dr. Patricia Carter, chief veterinarian at Helen Woodward Animal Center. "Then we gave him something that made him unsleepy, but hes still recovering from the surgery two days ago.

Dwayne is a warrior and shows his love to those who have love to give.

He is adorable, sweet and with everything that is going on, he wants to give you kisses and love, Schaffer said.

Over $40,000 has been donated to Dwayne for medical costs from around the world, including Paris. He also has had plenty of people giving well wishes and dropping off toys at the animal hospital.

The animal center posts updates on Dwayne and other orphan pets on itswebsite.

Go here to see the original:
Abused pup receives cutting-edge stem cell therapy - fox5sandiego.com

Entest BioMedical’s Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti … – PR Newswire (press release)

Based on the license agreement, Zander is able to benefit from the progress Regen BioPharma, Inc. makes in developing NR2F6 small molecule modulators for humans by testing the same drugs in animals. In partnership with Chem Div, Inc., an internationally recognized contract research organization, Zander has tested some initial compounds that act on human cells in suppressing the immune system in a small amount of dog blood. The results indicate that at least one of the compounds suppressed IL-17a expression in activated peripheral blood mononuclear cells in a non-toxic manner.

Zander is continuing similar experiments testing other compounds and will also begin to test anti-cancer small molecule compounds in the coming months.

The NR2F6 nuclear receptor has been identified as a potentially extremely important immune cell inhibitor and cancer stem cell differentiator. Molecules which function as immune cell inhibitors are called "immune checkpoints" and basically act as an "on or off switch" to an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system therefore therapies that target these checkpoints demonstrate tremendous potential as cancer treatments. The NR2F6 program at Zander Therapeutics focuses on identifying antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a dog's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

About Zander Therapeutics Inc. and Entest BioMedical Inc.:

Zander Therapeutics is a subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.

Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.

Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.

David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (subsidiary of Entest BioMedical Inc.).

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION Zander Therapeutics Inc. and Entest BioMedical Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax http://www.zandertherapeutics.com/ info@zandertherapeutics.com

SOURCE Entest BioMedical Inc.

Read the original here:
Entest BioMedical's Subsidiary Zander Therapeutics, Inc. Reports on Preliminary Canine Experiments Testing New Anti ... - PR Newswire (press release)

United Veterinary Center Norwalk Offers Stem Cell Therapy to Treat Pets Without Invasive Therapy – MilTech

Norwalk, CT United Veterinary Center Norwalk humbly announces that their veterinary clinic now offers stem cell therapy to treat pets without any invasive therapy. This Norwalk veterinarian is the first among any other veterinary clinic to offer such a groundbreaking procedure. With its release, pet lovers and owners who have pets with serious medical conditions can now avail of this procedure at their clinic. The research for the stem cell therapy was backed by the Kansas State University independent of MediVet Biologics based on the work of Dr. David A. Upchurch and Dr. Mark L. Weiss.

In a statement by Dr. Gil Stanzione, a CT veterinarian and one of their senior vets, he stated that Our team of medical experts is equipped with up to date advances in veterinary research and technology. Hereat the Center, our experienced Norwalk vet understands the value of your pet to your family. By adopting the stem cell therapy, the clinic stands firm to their word to provide their clients with the newest and latest procedures available. He also added that We are devoted to giving your pets the excellent healthcare and medical services they truly deserve. With the latest technology and state-of-the-art veterinary equipment available in our medical center in Norwalk, Connecticut, your beloved pets are safe in our hands.

The stem cell therapy this Norwalk veterinarian offers is called the ActiStem. The procedure involves an incorporation of a concentration of regenerative stem cells and other repair cells to the damaged portion of the pets body. With the procedure now available at their disposal, the fear of losing a precious member of the family will slowly decrease knowing that there is a veterinary clinic available to treat their pets. Pet owners can rest assured that the procedure their pet will undergo will have no adverse side effects and without the need of intensive therapy.

United Veterinary Center is a veterinary clinic that offers a variety of services and treatments for family pets. The services they offer include administration of vaccinations, wellness programs for pets to keep them healthy, dental care, as well as surgeries and microchip installations. The facilities and services that this Norwalk, CT vet offers are specially designed to take care of your pets. Their clinic can handle medical conditions that may require hospitalization or intensive care for their clients beloved pet.

To avail of their stem cell therapy, United Veterinary Center Norwalk is located at 48 Westport Avenue #2 Norwalk, CT 06851. To know more about the services and the procedures this Norwalk CT veterinarian offers, please visit their website at http://unitedveterinarycenter.com/, or call them at (203) 349-6895.

They can also be contacted via email at info@unitedveterinarycenter.com

Media Contact Company Name: United Veterinary Center Norwalk Contact Person: Dr. Gil Stanzione Email: info@unitedveterinarycenter.com Phone: (203) 349-6895 Address:48 Westport Avenue #2 City: Norwalk State: Connecticut Country: United States Website: http://unitedveterinarycenter.com/

Go here to read the rest:
United Veterinary Center Norwalk Offers Stem Cell Therapy to Treat Pets Without Invasive Therapy - MilTech

WEB EXCLUSIVE: Military father fights for his life – KSWO

FORT BRAGG, NC (KSWO)- Sgt. Jack Stillman- a Patriot system repairer with the 3rd Battalion, 4th Air Defense Artillery Regiment, 108th Air Defense Artillery Brigade- is by all accounts a good father, husband, brother, and soldier. Jack went through basic training right here at Fort Sill and just celebrated his 23rd birthday this week.

Despite extensive military training, deployments, PCSing and active duty service, thats not the hardest thing the Stillmans have been through. Cancer is the toughest battle hes ever been in.

Jack has Stage 4B Anaplastic Large T-Cell Lymphoma, an extremely rare and aggressive form of non-Hodgkin lymphoma with 75-85 percent five-year survival rate.

Army Sgt. Jack Stillman was diagnosed shortly aftermaking history by winning the Iron Warrior Award in September 2016 at the Basic Leader Course, Leadership Award, and a Distinguished Honor Graduate at Fort Bragg. Jack was diagnosed for the 1st time October 6th, 2016 after doctors found a dime sized lump under his left arm by his ribs.

We were about to sit down for dinner with the kids, and Jacks cell phone rang. The first thing we heard was, Were sorry to tell you this over the phone - wed rather consult face to face, but we need to get moving quickly. Jacks face went white, and he dropped the phone. Alina Stillman, Jacks wife, recalls.

The cancer spread rapidly. A PET scan exposed cancer in Jacks spleen, femur, spine, and bones.

The scan lit up like a Christmas tree, Alina says. He lost his eyebrows, his hair, and he gets so sick.

Alina and their two young sons, Aiden (6) and Jackson (4), are proud not only of Jacks service to our country but of his strength through all of the painful treatments and setbacks. Theyve watched as their rock and sole providers health has deteriorated. Alina can only describe this as if their world crumbling around them.

He started getting all the symptoms, Alina says. Night sweats, unbearable pain under his arm. He would get up at night and pace around, asking why is this happening?

Jack had emergency surgery to remove the lymph nodes and was in and out of the hospital for 6 months receiving chemotherapy. His wife never leaves his side. Alina is by his side praying every day for Jacks strength and endurance.

It was absolutely devastating to watch a strong man turn lifeless. His body was so frail. He lost around 20 pounds upon diagnosis. Our two boys came to visit him when Jack was admitted to the hospital for an infection he got when he had his first port put in, and you could tell how sad & frightened our boys were to see their daddy become a victim to this evil disease. There were many nights where I would lock myself in a bathroom and just cry and ask why.

Jack finished 6 rounds of aggressive (CHOEP) chemotherapy February 9th. One month later he was supposed to be on the road to recovery after showing great progress. The PET scan was clean, with just one slight hot spot that the doctors thought was just scar tissue where a lymph node had been removed. Jack was given the all clear on his last day of chemotherapy.

Just four weeks later, despite completing the harsh treatments, Jack fell ill again March 2017 with a 102.5-degree fever and severe calf pain. Another lump was found on Jacks leg. Doctors confirmed the Stillmans worst fearsthe stage 4 cancer has returned and, this time, it is even more aggressive than before.

Cancer is just so evil. I look at my husband and just feel so helpless because, in reality, there isn't anything I can do to make the pain go away, to make this evil disease flee from his body and never come back again. I wish I could take it all away. Some days it hits me harder than others. Some days I just want to curl up in a ball and scream.Soon Jack will begin to lose all his hair again, and his body will once again become frail. For the second time. A battle he's been fighting for 8 months, a battle that we had that we won

Jack has undergoing grueling high-dose chemotherapy in hopes that his body will respond to a clinical trial called CAR-T cell therapy at the University of North Carolina and an autologous stem cell transplant.

Currently, Jack is in remission but that doesnt mean he is out of the woods. This is just the first step towards getting the experimental treatment his family hopes will be the cure they are searching for. Jack will continue to receive brentuximab and intrathecal chemotherapy until the stem cell transplant. Doctors are performing tests to make sure Jack's body is ready for the transplant/CAR-T cell trial.

Our last chance of hope is a Stem Cell transplant along with a CD30 CAR T CELL clinical trial. Which he will begin in just a few weeks. The prep began a few months ago. They took out his T cells a few weeks ago and began re-engineering them, they will then infuse those t cells back into Jack, which is the clinical trial CAR-T CELL therapy part. The actual transplant part, they will remove his stem cells next week, and infuse them back into Jack on June 20th.

Up next, Jack will be in the hospital for 6 weeks for the transplant while he suffers through high doses of chemo and stem cell collection. Doctors will then re-engineer his cells and infuse them back into him.

For me, it is so hard to see the person you love most, fight for his life. It is absolutely devastating. & what's worse, is that there is nothing I can do to take this away from him, to make the cancer go away andto never come back. It breaks me. I have learned how to hold back tears because when I cry, my husband gets upset. But some days, it just hits me harder than other days, and holding in tears isn't possible. I cry, we cry. We shed tears together, but at the end of the day, I know that if anyone can beat this evil monster, it's my husband. He is the strongest person that I know. His motivation, positive attitude, and faith are what will get him through this.

But, prolonged hospital stays and being stationed far from their families makes maintaining a stable home life difficult. The couple works hard to fill their home and childrens lives with love and happiness but its not always possible to be together. Alina is a full-time caretaker for Jack and their children and therefore unable to work outside of the home.

Aiden asks me: 'mommy, why is daddy sick? How did daddy get sick?' How do you even begin to explain to a child just HOW sick their daddy is? Their Superman. Their all-time favorite superhero. The man that's been there since the beginning. Sick with cancer. A very rare type. A disease that has no cure. You can't. You can't sit there and stare into your child's face & tell them just HOW sick their father is. So you start to come up with ways to try to explain using kid-friendly terms where they understand daddy is sick, but not how sick. Cancer is ugly. It's an ugly disease. A disease that started with a small lump underneath my husband's left arm. The arms that hold me. The arms that he throws around our boys to give them the biggest hugs possible. and then the disease works its way through the body. Everywhere. Into his chest. The chest I rest my head on. The chest I shed thousands of tears on. The chest that carries the heart of the man I love so dearly. Cancer shows no mercy. It doesn't care that you're 22 years old, just beginning your life. That you have a whole life ahead of you. It doesn't care that you have 2 little boys ages 4 and 5 years old. It doesn't care that you have a wife. A wife that pleads to God day & night, for this disease to be taken away from the man she can't spend the rest of her life without. The man his family so dearly needs. I don't know why my husband has cancer. I don't know why he has such a rare form of it. But what I do know, is that we will keep on fighting. Because we are stronger than cancer. God is the ultimate physician. & our God is a miracle working God. We see miracles happen every day and soon, we will find ours."

The thing that stands out most about the Stillman family is their positivity and love of life, even in the worst of situations.

"Throughout my whole life I have gone through roadblocks that I never thought I would be able to overcome, but I did and this is just another one of those. Why? is the question I ask myself, why me? I am 100% percent healthy; go to the gym every day and eat like a health nut, never had a surgery before this one, the last time I got sick was when I was a junior in high school. The Dr. told me, It's just bad luck. Jack Stillman said the day of his diagnosis in October of 2016. I believe strongly that GOD will not give you something you can't handle and in the end once this is all over and I recover 100% it will make me a stronger man than I am today and us a stronger family. I am a warrior, a fighter, a husband, a dad, a son, a brother, a friend, a soldier and a follower of Christ. I WILL NOT let this get in the way, I WILL beat this, and WE WILL come out on top once again. Please send all your prayers to me and my family during this time and don't give up on us, because we will not give up on each other, said Jack.

We want to come out stronger than before. We are praying that this transplant & trial will work for Jack, and not only extend his life, but CURE him as well. We want our boys to learn to never give up on hope, faith, & determination, that anything is possible. We want them to look up to their daddy & to see inspiration. We want them to know that daddy will not stop fighting until this battle is won & behind us. Our greatest fear, is that this doesn't work. There's always that fear. But something in my gut tells me that this WILL work. A fear we will have forever, is knowing that this CAN come back again, & sometimes it comes back as a secondary cancer like leukemia. But right now, we will live in the moment, and take one day at a time. There's no sense in worrying about the future. A struggle during the transplant will be being away from our boys, from home, from our sweet puppy who has a magical bond with Jack. & Jack will be very sick, very ill, throughout the transplant. He will undergo very high dose chemo, that will completely wipe him out. & I am scared to be a witness to that, but I know he's got this, explained Alina.

The family is asking for prayers and support. If you would like to donate to the Stillmans rising medical and travel cost, click here.

Read more here:
WEB EXCLUSIVE: Military father fights for his life - KSWO

CSU breaks ground on $65M research institute – The Coloradoan

CSU President Tony Frank delivers groundbreaking remarks for new research center Nick Coltrain/Coloradoan

Dr. Wayne McIlwraith, second from left, participates in a groundbreaking ceremony for the C. Wayne McIlwraith Translational Medicine Institute, a $65 million research facility on the CSU campus, on Friday, June 2, 2017.(Photo: Tanya Fabian/For the Coloradoan)Buy Photo

Autoplay

Show Thumbnails

Show Captions

A group of VIPs donned hardhats some shaped like cowboy hats Friday afternoonand turned a shovelful of dirt near Colorado State University's Veterinary Teaching Hospital.

A few moments later, another group of VIPs patted down the dirtand performed the ceremonial groundbreaking again.

In some ways, it's a metaphor for the building that will go up in the space. Only instead of smoothing and repairing dirt, it will helpto heal and pioneer new techniques to heal both animals and humans.

"If you think about what is going to happen in this facility, we're going to be moving things," CSU President Tony Frank said, explaining the significance he sees in the name of the C. Wayne McIlwraith Translational Medicine Institute. "We're going to be moving things from the bench, from the laboratory into the hospital. We'll be moving from theory into practice. We'll be moving patients from disease into health."

Aside from the mighty aspirations of the $65 million research facility off the university's Drake Road veterinary campus, the new institutealso represents the single largest donation CSU has ever received.

John and Leslie Malone, who raise dressage and horses and thoroughbred racehorses,gave a "transformational" donation of $42.5 million for the facility, according to CSU.

Princess Abigail K. Kawananakoa of Hawaii, a longtime friend of the building's namesake CSU professor, largely rounded out the donations with a $20 million gift.

Kawananakoa breeds American quarter horses and McIlwraith long helped with the orthopaedic health essentially, the parts of the body in humans and animals that assist with movement and supportof her animals.

She and the Malones insisted that the building be named after McIlwraith, a distinguished professor in the CSU Department of Clinical Sciences, founding director of the CSU Orthopaedic Research Center and director of its musculoskeletal research program.

"I've known Wayne (McIlwraith) for 30 years, and hehas provided the world's best orthopaedic care for my horses," Kawananakoa said in a statement provided by CSU. "During this time, I've gained insights into the work of the CSU Orthopaedic Research Center and have seen first-hand how its discoveries improve horse health with novel approaches to treatment, prevention, and rehabilitation."

She was given an honorary doctorate by CSU in 2016.

While the major donors and McIlwraith are bound by mutual love for horses, the Translational Medicine Institute is designed to meet needs across species, with an eye toward potential commercialization of its discoveries.

CSU scientists will research therapies involving stem cells and other techniques for horses while also learning how they might translate into helping humans lead better lives.

Construction of the institute is expected to be complete in fall 2018.

This rendering shows the proposed Dr. C. Wayne McIlwraith Translational Medicine Institute expected to open at Colorado State University in fall 2018.(Photo: Colorado State University)

C. Wayne McIlwraith Translational Medicine Institute

Location: CSU South Campus, between Diagnostic Medical Center and Orthopaedic Research Center

Construction budget: $65 million

Funding sources: $42.5 million gift from John and Leslie Malone;$20 million gift from Princess Abigail Kawananakoa of Hawaii; additional state and CSU support

Anticipated completion: Fall 2018

Read or Share this story: http://noconow.co/2snPyWy

More:
CSU breaks ground on $65M research institute - The Coloradoan

Stem Cell Therapy in a Pill | Life Extension Magazine

1. Available at: http://archives.cnn.com/2001/TECH/science/11/25/human.embryo.clone. Accessed August 2, 2006.

2. Available at: http://www.hmnews.org/article2778.html. Accessed August 2, 2006.

3. Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004;24:105-31.

4. Fang TC, Alison MR, Cook HT, et al. Proliferation of bone marrow-derived cells contributes to regeneration after folic acid-induced acute tubular injury. J Am Soc Nephrol. 2005 Jun;16(6):1723-32.

5. Craciunescu CN, Brown EC, Mar MH, et al. Folic acid deficiency during late gestation decreases progenitor cell proliferation and increases apoptosis in fetal mouse brain. J Nutr. 2004 Jan;134(1):162-6.

6. Zittoun J. Anemias due to disorder of folate, vitamin B12 and transcobalamin metabolism. Rev Prat. 1993 Jun 1;43(11):1358-63.

7. Fishman SM, Christian P, West KP. The role of vitamins in the prevention and control of anaemia. Public Health Nutr. 2000 Jun;3(2):125-50.

8. Mathieu C, van EE, Decallonne B, et al. Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):449-52.

9. Hypponen E. Micronutrients and the risk of type 1 diabetes: vitamin D, vitamin E, and nicotinamide. Nutr Rev. 2004 Sep;62(9):340-7.

10. Gysemans CA, Cardozo AK, Callewaert H, et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology. 2005 Apr;146(4):1956-64.

11. Aslam SM, Garlich JD, Qureshi MA. Vitamin D deficiency alters the immune responses of broiler chicks. Poult Sci. 1998 Jun;77(6):842-9.

12. Wang AM, Ma C, Xie ZH, Shen F. Use of carnosine as a natural anti-senescence drug for human beings. Biochemistry (Mosc.). 2000 Jul;65(7):869-71.

13. Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. Free Radic Biol Med. 2000 May 15;28(10):1564-70.

14. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res. 1994 Jun;212(2):167-75.

15. McFarland GA, Holliday R. Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp Gerontol. 1999 Jan;34(1):35-45.

16. Yuneva MO, Bulygina ER, Gallant SC, et al. Effect of carnosine on age-induced changes in senescence-accelerated mice. J Anti-Aging Med. 1999;2(4):337-42.

17. Hipkiss AR, Preston JE, Himsworth DT, et al. Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann NY Acad Sci. 1998 Nov 20;854:37-53.

18. Holliday R, McFarland GA. A role for carnosine in cellular maintenance. Biochemistry (Mosc.). 2000 Jul;65(7):843-8.

19. Shao L, Li QH, Tan Z. L-carnosine reduces telomere damage and shortening rate in cultured normal fibroblasts. Biochem Biophys Res Commun. 2004 Nov 12;324(2):931-6.

20. Yuneva AO, Kramarenko GG, Vetreshchak TV, Gallant S, Boldyrev AA. Effect of carnosine on Drosophila melanogaster life span. Bull Exp Biol Med. 2002 Jun;133(6):559-61.

21. Hipkiss AR, Brownson C, Bertani MF, Ruiz E, Ferro A. Reaction of carnosine with aged proteins: another protective process? Ann NY Acad Sci. 2002 Apr;959:285-94.

22. Stuerenburg HJ. The roles of carnosine in aging of skeletal muscle and in neuromuscular diseases. Biochemistry (Mosc.). 2000 Jul;65(7):862-5.

23. Gallant S, Semyonova M, Yuneva M. Carnosine as a potential anti-senescence drug. Biochemistry (Mosc.). 2000 Jul;65(7):866-8.

24. Boldyrev A, Song R, Lawrence D, Carpenter DO. Carnosine protects against excitotoxic cell death independently of effects on reactive oxygen species. Neuroscience. 1999;94(2):571-7.

25. Boldyrev AA, Gallant SC, Sukhich GT. Carnosine, the protective, anti-aging peptide. Biosci Rep. 1999 Dec;19(6):581-7.

26. Preston JE, Hipkiss AR, Himsworth DT, Romero IA, Abbott JN. Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett. 1998 Feb 13;242(2):105-8.

27. Boldyrev AA, Stvolinsky SL, Tyulina OV, et al. Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free radicals. Cell Mol Neurobiol. 1997 Apr;17(2):259-71.

28. Horning MS, Blakemore LJ, Trombley PQ. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res. 2000 Jan 3;852(1):56-61.

29. Braser P. Blueberries may aid balance, memory. Associated Press. September 17, 1999.

30. Galli RL, Bielinski DF, Szprengiel A, Shukitt-Hale B, Joseph JA. Blueberry supplemented diet reverses age-related decline in hippocampal HSP70 neuroprotection. Neurobiol Aging. 2006 Feb;27(2):344-50.

31. Andres-Lacueva C, Shukitt-Hale B, Galli RL, et al. Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. Nutr Neurosci. 2005 Apr;8(2):111-20.

32. Wang Y, Chang CF, Chou J et al. Dietary supplementation with blueberries, spinach, or spirulina reduces ischemic brain damage. Exp Neurol. 2005 May;193(1):75-84.

33. de RC, Shukitt-Hale B, Joseph JA, Mendelson JR. The effects of antioxidants in the senescent auditory cortex. Neurobiol Aging. 2006 Jul;27(7):1035-44.

34. Willis L, Bickford P, Zaman V, Moore A, Granholm AC. Blueberry extract enhances survival of intraocular hippocampal transplants. Cell Transplant. 2005;14(4):213-23.

35. Lau FC, Shukitt-Hale B, Joseph JA. The beneficial effects of fruit polyphenols on brain aging. Neurobiol Aging. 2005 Dec;26 Suppl 1:128-32.

36. Matchett MD, MacKinnon SL, Sweeney MI, Gottschall-Pass KT, Hurta RA. Blueberry flavonoids inhibit matrix metalloproteinase activity in DU145 human prostate cancer cells. Biochem Cell Biol. 2005 Oct;83(5):637-43.

37. Casadesus G, Shukitt-Hale B, Stellwagen HM, et al. Modulation of hippocampal plasticity and cognitive behavior by short-term blueberry supplementation in aged rats. Nutr Neurosci. 2004 Oct;7(5-6):309-16.

38. Joseph JA, Shukitt-Hale B, Denisova NA, et al. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J Neurosci. 1999 Sep 15;19(18):8114-21.

39. Chen ZP, Schell JB, Ho CT, Chen KY. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998 Jul 17;129(2):173-9.

40. Wang YC, Bachrach U. The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). Amino Acids. 2002;22(2):131-43.

41. Whetton AD, Spooncer E. Role of cytokines and extracellular matrix in the regulation of haemopoietic stem cells. Curr Opin Cell Biol. 1998 Dec;10(6):721-6.

42. Gemma C, Mesches MH, Sepesi B, et al. Diets enriched in foods with high antioxidant activity reverse age-induced decreases in cerebellar beta-adrenergic function and increases in proinflammatory cytokines. J Neurosci. 2002 Jul 15;22(14):6114-20.

43. Bickford PC, Tan J, Shytle RD, et al. Nutraceuticals synergistically promote proliferation of human stem cells. Stem Cells Dev. 2006 Feb;15(1):118-23.

44. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991 Dec 1;78(11):2791-808.

45. Available at: http://www.aafp.org/afp/20001001/1565.html. Accessed August 2, 2006.

46. Available at: http://www.cnn.com/2006/TECH/science/06/07/harvard.cloning.ap/index.html. Accessed August 2, 2006.

Original post:
Stem Cell Therapy in a Pill | Life Extension Magazine

Canine Stem Cell Therapy Market Research Report Now Available … – Thrasher Backer

Research Corridor has published a new research study titled Canine Stem Cell Therapy Market Growth, Share, Opportunities, Competitive Analysis and Forecast, 2017 2025. The Canine Stem Cell Therapy market report studies current as well as future aspects of the Canine Stem Cell Therapy Market based upon factors such as market dynamics, key ongoing trends and segmentation analysis. Apart from the above elements, the Canine Stem Cell Therapy Market research report provides a 360-degree view of the Canine Stem Cell Therapy industry with geographic segmentation, statistical forecast and the competitive landscape.

Browse the complete report at http://www.researchcorridor.com/canine-stem-cell-therapy-market/

Geographically, the Canine Stem Cell Therapy Market report comprises dedicated sections centering on the regional market revenue and trends. The Canine Stem Cell Therapy market has been segmented on the basis of geographic regions into North America, Europe, Asia Pacific and Rest of the World (RoW). The RoW segment consists Latin America and the Middle East & Africa. The Canine Stem Cell Therapy market has been extensively analyzed on the basis of various regional factors such as demographics, gross domestic product (GDP), inflation rate, acceptance and others. Canine Stem Cell Therapy Market estimates have also been provided for the historical years 2015 & 2016 along with forecast for the period from 2017 2025.

The research report also provides a comprehensive understanding of Canine Stem Cell Therapy market positioning of the major players wherein key strategies adopted by leading players has been discussed. The Canine Stem Cell Therapy industry report concludes with the Company Profiles section which includes information on major developments, strategic moves and financials of the key players operating in Canine Stem Cell Therapy market.

Key Takeaways:

Market Dynamics in the Canine Stem Cell Therapy Market

Key Ongoing Regional Trends

Canine Stem Cell Therapy Market Estimates for Years 2014 2025

Canine Stem Cell Therapy Market Positioning of Key Players

Key Strategies Adopted by the Leading Players

Attractive Investment Proposition

Canine Stem Cell Therapy Market Inclination Insights

Related Reports

http://www.researchcorridor.com/diabetes-management-platform-market/

http://www.researchcorridor.com/sterile-sampling-systems-market/

Pelvic Trauma Management

About Research Corridor

Research Corridor provides End to End Solution for Market Research Consulting and Custom Research Reports. Database of Over 42000 Global Market Reports Research Corridor is world leading company in syndicated market Research Reports.

For More Information, Visit Research Corridor

Media ContactCompany Name: Research CorridorContact Person: VikramEmail: sales@researchcorridor.com

Go here to see the original:
Canine Stem Cell Therapy Market Research Report Now Available ... - Thrasher Backer

Back to Top